A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY
William Sandborn 1
1 University of California San Diego
Pathway
Chairman's Choice, Digestive Oncology, Disease Mechanisms, Endoscopy, Gut Microbiota, Hepatobiliary, Histopathology, IBD, Immunology, Neurogastroenterology & Motility, Oesophagus, Paediatrics, Pancreas, Primary Care, Radiology & Imaging, Small Intestine & Nutrition, Stomach & H. Pylori, Surgery, Young GI Track
Session
Opening Plenary Session
Conference
UEG Week 2015
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing